 - Nanoparticle-based technology complements the companys intratumoral technology platform - NOVATO, CA ACCESSWIRE October 6, 2021 Mosaic ImmunoEngineering, Inc. Mosaic or the Company, OTCQB:CPMV, a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, today announced that it has licensed rights to develop and commercialize new treatment candidates that broaden the scope and capabilities of the Companys protein nanoparticle platform to treat cancer. The technology involves the loading of immuno-stimulatory molecules into plant virus protein nanoparticles. 